Research programme: paracetamol prodrugs - NeurogesX

Drug Profile

Research programme: paracetamol prodrugs - NeurogesX

Alternative Names: NGX-1576; NGX-5752; NGX-9674

Latest Information Update: 14 May 2012

Price : $50

At a glance

  • Originator NeurogesX
  • Class
  • Mechanism of Action Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 03 May 2012 NeurogesX is still seeking business development partners to advance its paracetamol prodrug programme
  • 30 May 2011 Preclinical development is ongoing in USA
  • 20 Mar 2009 Preclinical trials in Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top